Clinical Trial Update: A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating SHR-1826 as monotherapy or in combination with immunotherapy for advanced hepatocellular carcinoma; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• SHR-1826

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Cancer | Phase 2 | Status: NOT_YET_RECRUITING